Interactions Between Buprenorphine and the Protease Inhibitors Darunavir-Ritonavir and Fosamprenavir-Ritonavir | Zendy

Valerie A. Gruber | Zendy; Petrie M. Rainey | Zendy; David E. Moody | Zendy; Gene D. Morse | Zendy; Qing Ma | Zendy; Sudha Prathikanti | Zendy; Patricia Pade | Zendy; Anika Alvanzo | Zendy; Elinore F. McCanceKatz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Interactions Between Buprenorphine and the Protease Inhibitors Darunavir-Ritonavir and Fosamprenavir-Ritonavir

Author(s) -

Valerie A. Gruber,

Petrie M. Rainey,

David E. Moody,

Gene D. Morse,

Qing Ma,

Sudha Prathikanti,

Patricia Pade,

Anika Alvanzo,

Elinore F. McCanceKatz

Publication year - 2011

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cir799

Subject(s) - darunavir , ritonavir , medicine , buprenorphine , virology , protease inhibitor (pharmacology) , pharmacology , human immunodeficiency virus (hiv) , opioid , viral load , antiretroviral therapy , receptor

This study examined drug interactions between buprenorphine, a partial opioid agonist used for opioid dependence treatment and pain management, and the protease inhibitors (PIs) darunavir-ritonavir and fosamprenavir-ritonavir.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research